The full Eli Lilly (LLY) reaction history

Every LLY news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the LLY overview →

By year and event type

LLY reaction counts across 4 years.

Event type2026202520242023Total
Press release761169342327
SEC filing · Form 8-K5913128
SEC filing · Form 10-Q23319
SEC filing · Form 10-K11103
SEC filing · Form 11-K11103
SEC filing · Form DEF11103
SEC filing · Form DEFA14A11103
SEC filing · Form PRE11103
SEC filing · Form SD11103
SEC filing · Form S-3ASR01001
All types8913511544383

Counts from the full measured window for LLY, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older LLY news pages.

Page 1 is the LLY overview; pages 2–8 carry the rest of the measured list.

The 10 most recent LLY reactions.

DateHeadlineEventSource5-minTo close
Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black marketPress releasePR Newswire+0.17%+1.67%
Form 10-Q ELI LILLY & Co For: Jun 30SEC filing · Form 10-QSEC EDGAR+0.15%+0.96%
Form 8-K ELI LILLY & Co For: Aug 05SEC filing · Form 8-KSEC EDGAR+2.15%-1.59%
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressPress releasePR Newswire+2.15%-1.59%
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerPress releasePR Newswire-1.07%-2.66%
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1CPress releasePR Newswire+2.07%+3.84%
Lilly confirms date and conference call for second-quarter 2026 financial results announcementPress releasePR Newswire+0.01%+0.26%
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditionsPress releasePR Newswire-0.78%+1.23%
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatmentPress releasePR Newswire+1.26%+0.44%
Lilly Canada receives long-awaited Ebglyss® CDA-AMC recommendation as well as pCPA LOI for atopic dermatitis (eczema)Press releaseCanada Newswire+0.56%+0.33%

373 more LLY reactions are behind a free account. Create one to see all 383 measured LLY events — the same point-in-time reactions, every headline.

See all 383 LLY events →

No credit card · 1,000 free credits/mo